MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells

Abstract

The chemokine CXCL12 regulates the interaction between hematopoietic stem and progenitor cells and bone marrow stromal cells. Although its relevance in the bone marrow niche is well recognized, the regulation of CXCL12 by microRNA is not completely understood. We transfected a library of 486 microRNA in the bone marrow stromal cell line SCP-1 and studied the expression of CXCL12. Twenty-seven microRNA were shown to downregulate expression of CXCL12. Eight microRNA (miR-23a, 130b, 135, 200b, 200c, 216, 222, and 602) interacted directly with the 3´UTR of CXCL12. Next, we determined that only miR-23a is predicted to bind to the 3´UTR and is strongly expressed in primary bone marrow stromal cells. Modulation of miR-23a changes the migratory potential of hematopoietic progenitor cells in co-culture experiments. We discovered that TGFB1 mediates its inhibitory effect on CXCL12 levels by upregulation of miR-23a. This process was partly reversed by miR-23a molecules. Finally, we determined an inverse expression of CXCL12 and miR-23a in stromal cells from patients with myelodysplastic syndrome indicating that the interaction has a pathophysiological role. Here, we show for the first time that CXCL12-targeting miR23a regulates the functional properties of the hematopoietic niche. MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells ABSTRACT © F e r r a t a S t o r t i F o u n d a t i o nproteases. 11,12 Furthermore, CXCL12 expression can be transcriptionally modulated by a variety of cytokines and growth factors, namely transforming growth factor-beta 1 (TGFB1). TGFB1 has a negative growth effect on HSPC which is mediated, in part, by the regulation of CXCL12 arising from stromal cells. 13 Thus, engraftment and response to cytotoxic drugs may vary according to CXCL12 levels provided by niche cells. 14,15 Recently, Pillai et al. suggested that CXCL12 can also be regulated by microRNA (miRNA) in human marrow stromal cells. 16 There are more than 1000 miRNA which form 1-2% of the human genome. Approximately half of human structural genes are predicted to be under miRNA control. In animals, miRNA act by targeting the 3ú ntranslated region (UTR) of genes with the consequence of repressing output of the respective protein. A classical switch interaction is used to avoid protein expression in a particular cell type, whereas tuning interactions are needed to supply the cell with the optimal level of protein. 17 In the hematopoietic system, CXCL12 must be fine-tuned in response to differing physiological requirements.We, therefore, decided to study the interaction of CXCL12 and miRNA by applying a strategy of overexpression of a library to reveal the various miRNA responsible for CXCL12 regulation in primary human bone marrow stromal cells (hBMSC). Moreover, we mapped expression of candidate miRNA in primary hBMSC to understand their physiological function in fine tuning CXCL12 expression in the hematopoietic niche. Methods Cell linesHS5, HS27, HL60, K562, KG1a, and HeLa cell lines were ob...

Cell-Cell Communication Networks Propose a Modulation of the Hematopoietic Stem Cell Niche by Invading Breast Carcinoma Cells

“…Our group recently confirmed a reduction of SDF-1 mRNA and protein levels as well as a reduced SDF-1 promoter activity in MSC after supernatant transfer from breast cancer cells [64]. As potential mediators of this, we identified an enhanced expression of the TGF-β1 cytokine, downregulation of the SP1 transcription factor as well as increased levels of the posttranscriptional regulator miR23-a [64,65]. Another potential mediator of paracrine MSC modulation by BCC is FGF-2, which was apparently upregulated in SCP-1 after MCF-7 supernatant transfer and is reported to inhibit SDF-1 expression in bone marrow stromal cells [66].…”

Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12

“…Activating transcription factor (ATF3) may be one candidate which is involved in activation of TGFβ signaling in MSCs since we detected an increased expression in SCP‐1/MCF‐7 microarrays (not shown). Furthermore, we have demonstrated a post‐transcriptional regulation of both TGFβ1 and CXCL12 in the hematopoietic niche by miR‐23a …”

“…For human MSCs we determined miR‐23a as the most potent modulator of CXCL12 expression and function. This refers to the ability of miR‐23a to change the migratory potential of HSPCs in a coculture with primary MSCs as well as to the expression changes during differentiation of MSCs toward adipocytes and osteoblasts . Micro RNAs were shown to participate in many steps of cancer progression including metastasis by suppression of their target mRNAs .…”

Deep serum discoveries: SDF‐1α and HSA fragments in myelodysplastic syndromes

“…2B). That may be explained by disturbed transforming growth factor-b (TGF-b)/Smad signaling in MDS [10] transcriptionally modulating SDF-1a gene expression and causing down-regulated SDF-1a production of MDS mesenchymal stromal cells of [11,12]. Furthermore, a higher expression of CXCR4, the SDF-1a receptor on hematopoietic cells, was recently identified to be a prognostic factor for overall and progression-free survival in MDS patients [13], which might be an attempt to compensate the reduced SDF-1a levels.…”